Suspension of trading

OPTINOSEPAR Stock

OPTN

US68404V2097

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 21/05/2025 HKT			5-day change	1st Jan Change
9.600 ^USD	-1.13%		-.--%	-

23/05/25	OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P Global BMI Index	CI
23/05/25	OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P TMI Index	CI

Analysts' recommendations: OPTINOSEPAR

21/03/25	HC Wainwright Downgrades OptiNose to Neutral From Buy, Cuts Price Target to $9 From $18	MT
21/03/25	Piper Sandler Downgrades OptiNose to Neutral From Overweight, $9 Price Target	MT
20/03/25	Lake Street Downgrades OptiNose to Hold From Buy, Price Target is $9	MT
18/03/24	Lake Street Adjusts Price Target on OptiNose to $4 From $3, Maintains Buy Rating	MT
11/03/24	HC Wainwright Initiates OptiNose With Buy Rating, $5 Price Target	MT

More recommendations

News in other languages: OPTINOSEPAR

21/03/25

USA-Les valeurs à suivre à Wall Street (actualisé)

More news

Managers and Directors: OPTINOSEPAR

Manager	Title	Age	Since
Evan Loh CEO	Chief Executive Officer	67	21/05/2025
Michael C. Berkey CTO	Chief Tech/Sci/R&D Officer	-	01/01/2020
Jonathan Neely IRC	Investor Relations Contact	-	01/08/2020

Director	Title	Age	Since
Evan Loh BRD	Director/Board Member	67	21/05/2025

More insiders

OptiNose, Inc. is a specialty pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. It has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.

Employees

128

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
OPTN Stock

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	97.22M 84.78M 80.05M 72.69M 136M 9.33B 137M 959M 370M 4.74B 365M 357M 15.26B	P/E 2023	-4.07x	P/E 2024	-3.15x
Enterprise Value	142M 124M 117M 106M 198M 13.6B 199M 1.4B 539M 6.91B 532M 520M 22.24B	EV / Sales 2023	2.86x	EV / Sales 2024	1.43x
Free-Float	6.21%	Yield 2023 *	-	Yield 2024	-

23/05/25	OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P Global BMI Index	CI
23/05/25	OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P TMI Index	CI
22/05/25	BioPharma Credit Receives $83 Million from OptiNose Sale	MT
21/05/25	Paratek Pharmaceuticals, Inc completed the acquisition of OptiNose, Inc. from group of shareholders.	CI
21/05/25	OptiNose, Inc. Announces Management Changes	CI
21/05/25	OptiNose, Inc.(NasdaqGM:OPTN) dropped from NASDAQ Composite Index	CI
15/05/25	OptiNose, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
26/03/25	OptiNose Q4 Income From Operations USD 354 Thousand	RE
26/03/25	OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
26/03/25	OptiNose, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/03/25	HC Wainwright Downgrades OptiNose to Neutral From Buy, Cuts Price Target to $9 From $18	MT
21/03/25	Health Care Flat on Defensive Demand -- Health Care Roundup	DJ
21/03/25	Sector Update: Health Care Stocks Edge Higher Late Afternoon	MT

21/05/25	Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies	AQ
15/05/25	OptiNose: Q1 Earnings Snapshot	AQ
30/04/25	OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN	BU
26/03/25	OptiNose: Q4 Earnings Snapshot	AQ
26/03/25	Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights	AQ

3 years	4.81	31.5
5 years	4.81	64.5
10 years	4.81	450

Date	Insider	Type	Main position	Quantity	% Market Cap.
21/5/25	Paul Kohler	Issuer sale	Chief Financial Officer	82,491	0.8204%
21/5/25	Kyle Dempsey	Issuer sale	Director	12,624	0.1255%
21/5/25	Eric Bednarski	Issuer sale	Director	12,624	0.1255%

OPTINOSEPAR Stock

Stocks

OPTN

US68404V2097

Pharmaceuticals

Valuation: OPTINOSEPAR

Latest news: OPTINOSEPAR

Analysts' recommendations: OPTINOSEPAR

Press Releases: OPTINOSEPAR

News in other languages: OPTINOSEPAR

Quotes and Performance

Price Extremes

Managers and Directors: OPTINOSEPAR

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OPTINOSEPAR	-1.13%	-.--%	-.--%	-53.62%	97.22M
ELI LILLY AND COMPANY	+0.04%	+3.34%	+51.12%	+101.82%	1,028B
JOHNSON & JOHNSON	-0.09%	+1.66%	+55.02%	+66.18%	651B
ABBVIE INC.	-0.02%	+2.66%	+18.91%	+71.47%	466B
ROCHE HOLDING AG	-1.22%	+3.66%	+36.44%	+38.32%	346B
NOVARTIS AG	-0.79%	+2.73%	+19.03%	+25.08%	266B
ASTRAZENECA PLC	+0.58%	+6.76%	+11.13%	+16.52%	259B
AMGEN INC.	+1.55%	+2.20%	+39.81%	+46.55%	208B
NOVO NORDISK A/S	+0.79%	+1.84%	-28.27%	-56.71%	191B
GILEAD SCIENCES, INC.	-0.52%	+4.45%	+32.12%	+98.51%	186B
Average	+0.07%	+2.93%	+23.53%	+35.41%	360.18B
Weighted average by Cap.	+0.23%	+3.09%	+35.15%	+61.76%

	2023	2024
Net sales	70.99M 61.9M 58.45M 53.08M 99.44M 6.81B 99.86M 700M 270M 3.46B 267M 261M 11.14B	78.23M 68.21M 64.41M 58.49M 110M 7.51B 110M 772M 298M 3.82B 294M 287M 12.28B
Net income	-35.48M -30.94M -29.22M -26.53M -49.71M -3.4B -49.91M -350M -135M -1.73B -133M -130M -5.57B	-21.54M -18.78M -17.74M -16.11M -30.18M -2.07B -30.3M -212M -81.99M -1.05B -80.92M -79.12M -3.38B
Net Debt	58.06M 50.63M 47.81M 43.41M 81.34M 5.57B 81.68M 573M 221M 2.83B 218M 213M 9.11B	44.48M 38.78M 36.62M 33.25M 62.3M 4.27B 62.56M 439M 169M 2.17B 167M 163M 6.98B